ResearcherAnhui Medical UniversityNo recent work listed

Ping Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8515-9106; OpenAlex author ID A5100442337. Sources: OpenAlex.

Their work

Papers: 3 (first author 1, last author 2)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper

Papers 3

Xanthatin suppresses pancreatic cancer cell growth via the ROS/RBL1 signaling pathway: In vitro and in vivo insights. First author DOI 10.1016/j.phymed.2023.155004 ↗
Long Noncoding RNA PSMA3 Antisense RNA 1 Promotes Cell Proliferation, Migration, and Invasion in Pancreatic Ductal Adenocarcinoma Via Targeting MicroRNA-154-5p… Last author DOI 10.1097/mpa.0000000000002136 ↗
A Panel of 12-lncRNA Signature Predicts Survival of Pancreatic Adenocarcinoma. Last author DOI 10.7150/jca.27823 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yadi Geng · 1 shared paper, 2023 · strength 0.20
- Paper Xanthatin suppresses pancreatic cancer cell growth via the ROS/RBL1 signaling pathway: In vitro and in vivo insights. DOI 10.1016/j.phymed.2023.155004 ↗
Lei Zhang · 1 shared paper, 2023 · strength 0.20
- Paper Xanthatin suppresses pancreatic cancer cell growth via the ROS/RBL1 signaling pathway: In vitro and in vivo insights. DOI 10.1016/j.phymed.2023.155004 ↗
Jiancheng Bi · 1 shared paper, 2022 · strength 0.19
- Paper Long Noncoding RNA PSMA3 Antisense RNA 1 Promotes Cell Proliferation, Migration, and Invasion in Pancreatic Ductal Aden… DOI 10.1097/mpa.0000000000002136 ↗
Huo Zhang · 1 shared paper, 2019 · strength 0.08
- Paper A Panel of 12-lncRNA Signature Predicts Survival of Pancreatic Adenocarcinoma. DOI 10.7150/jca.27823 ↗
Xin Min ZHOU · 1 shared paper, 2019 · strength 0.08
- Paper A Panel of 12-lncRNA Signature Predicts Survival of Pancreatic Adenocarcinoma. DOI 10.7150/jca.27823 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.